Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation- in the US
Shots:
- On 28 Nov- 2018 Xospata (gilteritinib) received FDA approval as a PO monothx- indicated for r/r FLT3 mutation-positive (FLT3mut+) AML
- Xospata is accompanied by Xospata Support Solutions offering access and reimbursement support to patients and also provides information regarding patient healthcare coverage options and financial assistance programs
- Xospata 40 mg (gilteritinib) is a FLT3 inhibitor- approved by Japan Ministry of Health- Labor and Welfare (MHLW) for r/r AML with FLT3 mutations and is being evaluated in P-III for multiple FLT3 mutation-positive AML
Ref: Astellas | Image: Astellas
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
